Vidéocours
le (3m31s)
Résultats de recherche
Trier par :
Nombre de programmes trouvés : 5426
Conférences
le (36m37s)
Penser l'attachement parental dans l'adoption internationale / Diana Miconi
Penser l'attachement parental dans l'adoption internationale / Diana Miconi, in colloque "Parentalités contemporaines", organisé par le Laboratoire Clinique Psychopathologique et Interculturelle (LCPI) et le GIS "Recherche et clinique périnatale" sous la responsabilité scientifique de Sylvie Bourdet-Loubère et Delphine Rambeaud-Collin, Université Toulouse Jean Jaurès, 5-7 juin 2019.Les parentalités contemporaines sont autant de façons de « faire famille » c’est à dire de fonder, d’être une famille et se situent donc à l’interface de champs différents : sociologiques, juridiques, politiques, scientifiques et à ce titre interrogent également le ... Voir la vidéo
Conférences
le (7m14s)
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Regulatory viewpoint (Angeles ALONSO)
... development of new antithrombotic agents is a challenging area of cardiovascular medicine.These agents generally have a narrow therapeutic margin, and it is often difficult to find the optimal balance between efficacy (reduction of ischemic events) and safety... Voir la vidéo
Conférences
le (8m8s)
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Industry viewpoint (Christophe GAUDIN)
... development of new antithrombotic agents is a challenging area of cardiovascular medicine.These agents generally have a narrow therapeutic margin, and it is often difficult to find the optimal balance between efficacy (reduction of ischemic events) and safety... Voir la vidéo
Conférences
le (8m25s)
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Regulatory viewpoint (Kaori SHINAGAWA)
... development of new antithrombotic agents is a challenging area of cardiovascular medicine.These agents generally have a narrow therapeutic margin, and it is often difficult to find the optimal balance between efficacy (reduction of ischemic events) and safety... Voir la vidéo
Conférences
le (12m37s)
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : New indications: Is heart failure a viable new potential indication for anti-thrombosis therapy (Lloyd HASKEL)
... development of new antithrombotic agents is a challenging area of cardiovascular medicine.These agents generally have a narrow therapeutic margin, and it is often difficult to find the optimal balance between efficacy (reduction of ischemic events) and safety... Voir la vidéo
Conférences
le (17m49s)
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Different doses, different indications? (Maarten SIMOONS)
... development of new antithrombotic agents is a challenging area of cardiovascular medicine.These agents generally have a narrow therapeutic margin, and it is often difficult to find the optimal balance between efficacy (reduction of ischemic events) and safety... Voir la vidéo
Conférences
le (15m22s)
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Dosing Issues, Questions
... development of new antithrombotic agents is a challenging area of cardiovascular medicine.These agents generally have a narrow therapeutic margin, and it is often difficult to find the optimal balance between efficacy (reduction of ischemic events) and safety... Voir la vidéo
Conférences
le (6m44s)
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Industry viewpoint (Yasser KHDER)
... development of new antithrombotic agents is a challenging area of cardiovascular medicine.These agents generally have a narrow therapeutic margin, and it is often difficult to find the optimal balance between efficacy (reduction of ischemic events) and safety... Voir la vidéo
Conférences
le (23m46s)
